文献速递药物相互作用

达拉他韦与二甲双胍在健康志愿者中无药代-药效相互作用

Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
PubMed 文献 · Br J Clin Pharmacol · 2017-06-06

本研究为开放标签、两周期、随机交叉试验,纳入20名健康受试者,评估OCT抑制剂达拉他韦对OCT底物二甲双胍药代和药效的影响。结果显示二甲双胍AUC0-12、Cmax和Clast的几何均值比(90%CI)分别为109%(102-116%)、108%(101-116%)和112%(103-122%),达拉他韦不影响二甲双胍药代动力学,药效参数也相当。

要点

  • 达拉他韦不改变二甲双胍稳态药代参数,生物等效性分析成立。
  • 口服葡萄糖耐量试验中胰岛素、葡萄糖和乳酸水平两治疗组相当。
  • 临床联用达拉他韦与二甲双胍时无需基于此相互作用调整剂量。

核心结论

  • 达拉他韦不影响健康受试者二甲双胍的药代动力学,药效参数也相当。

研究设计与样本

  • 开放标签、两周期、随机交叉试验,纳入20名健康受试者。
  • 治疗A为二甲双胍,治疗B为二甲双胍+达拉他韦,稳态下记录药代曲线。

主要发现

  • 二甲双胍AUC0-12、Cmax和Clast的几何均值比(B vs. A,90%CI)分别为109%(102-116%)、108%(101-116%)和112%(103-122%)。
  • 治疗A和B期间胰岛素AUC0-2几何均值分别为84 h·mEl-1和90 h·mEl-1。
  • 治疗A和B期间葡萄糖AUC0-2几何均值分别为13.6 h·mmol l-1和13.4 h·mmol l-1。
  • 治疗A和B期间乳酸AUC0-2几何均值分别为3.4 h·mmol l-1和3.5 h·mmol l-1。

关键数值与推荐

  • 二甲双胍AUC0-12的几何均值比90%CI为102-116%,落在生物等效性范围内。

临床怎么用

  • 临床联用达拉他韦与二甲双胍时,无需因药代相互作用调整二甲双胍剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of the present study was to evaluate the effect of the proposed organic cation transporter (OCT) inhibitor daclatasvir on the pharmacokinetics and pharmacodynamics of the OCT substrate metformin. METHODS: This was an open-label, two-period, randomized, crossover trial in 20 healthy subjects. Treatment A consisted of metformin and treatment B consisted of metformin + daclatasvir. Pharmacokinetic curves were recorded at steady-state. Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated for metformin area under the concentration-time curve from 0 h to 12 h (AUC0-12 ), maximum plasma concentration (Cmax ) and final plasma concentration (Clast ). An oral glucose tolerance test was performed, measuring insulin, glucose and lactate levels. RESULTS: The GMRs (90% CI) of metformin AUC0-12 , Cmax and Clast (B vs. A) were 109% (102-116%), 108% (101-116%) and 112% (103-122%). The geometric mean AUC0-2 for insulin, glucose and lactate during treatments A and B were 84 h. mEl-1 and 90 h. mEl-1 , 13.6 h. mmol l-1 and 13.4 h. mmol l-1 , and 3.4 h. mmol l-1 and 3.5 h. mmol l-1 , respectively. CONCLUSIONS: Bioequivalence analysis showed that daclatasvir does not influence the pharmacokinetics of metformin in healthy subjects. Pharmacodynamic parameters were also comparable between treatments.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Smolders EJ, Colbers A, de Kanter CTMM, et al. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. Br J Clin Pharmacol. 2017. PMID: 28474741. doi:10.1111/bcp.13323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。